Cayman Alternative Investment Summit Announces 2016

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cayman Alternative Investment Summit Announces 2016 Industry Speakers

GRAND CAYMAN, Cayman Islands , Dec. 14, 2015 (GLOBE NEWSWIRE) -- The Cayman Alternative Investment Summit, which will take place February 4 and 5 at The Ritz-Carlton, Grand Cayman, has announced its industry speaker lineup, which includes John Mauldin, Christopher McChesney, Raoul Pal, Tarun Ramadorai, Anne Richards, Nouriel Roubini and Bruce Zimmerman.

Held at the Ritz-Carlton Grand Cayman, the fourth annual event titled “Alternative Investments: Supercharged” is expected to attract 500-plus executives from prominent pension plans, endowments, family offices, hedge funds and more. The summit provides opportunities for attendees to learn from and network with global alternative investment leaders.

“This impressive list of industry leaders will be well-received by our attendees,” said Anthony Cowell, partner and head of investments for KPMG and editorial chair for the 2016 Cayman Alternative Investment Summit. “Over the past three years, we have consistently brought the best and brightest minds to CAIS, and this year’s event will cement our place as the global voice of the alternative industry.”

John Mauldin is a renowned financial expert, New York Times best-selling author, pioneering online commentator and the publisher of one of the first publications to provide investors with free, unbiased information and guidance – Thoughts from the Frontline – one of the most widely read investment newsletters in the world. Mauldin’s company, Mauldin Economics, publishes a growing number of investing resources, including both free and paid publications aimed at helping investors do better in today’s challenging economy. In addition to publishing, Mauldin is cosponsor and host of the Strategic Investment Conference—an annual event for accredited investors that draws a faculty of some of the most respected investment and economic luminaries in the world.

Christopher McChesney is a senior vice president at Brown Brothers Harriman (BBH). Since 2012, he has led BBH’s global alternative funds business, which includes banking, administration and technology services to approximately $250 billion of private equity, real estate and hedge funds. McChesney is a regular speaker at industry events on topics related to alternative investment funds. Prior to joining BBH, he worked for The Boston Consulting Group where he helped the company expand its footprint in European and Asian markets.

Raoul Pal writes and publishes The Global Macro Investor, an elite macro economic and investment strategy research service for the world’s leading hedge funds, pension funds, banks and sovereign wealth funds. He has 24 years of experience in the financial markets working for investments banks such Goldman Sachs, where he co-managed the hedge fund sales business in equities and equity derivatives, as well as founding and managing a macro hedge fund for GLG Partners, ones of the world’s largest hedge fund firms. Additionally, Pal is the author of “The End Game” which is the most read financial article in the history of the Internet.

Tarun Ramadorai is a Professor of Financial Economics at the Saïd Business School, University of Oxford. His main areas of research interest are asset pricing and asset management, international finance, household finance and the Indian economy. Ramadorai has published extensively on these topics in a range of financial scholarly journals. He has served as an Economic Advisor to the European Securities and Markets Authority, as Honorary Advisor to the National Institute of Public Finance and Policy in New Delhi, and during 2011 and 2012, he was Visiting Scholar at the Economic Advisory Council to the Prime Minister of India.

Anne Richards graduated with a First Class Honours degree in Electronics and Electrical Engineering from the University of Edinburgh. After completing a research fellowship at CERN, the European Organisation for Nuclear Research in Geneva, she spent two years with Cambridge Consultants before taking a year out to study for an MBA at Insead in Fontainebleau, France. She began her city career as an analyst with Alliance Capital in 1992, subsequently moving onto portfolio management, firstly with JP Morgan Investment Management, and then with Mercury Asset Management, later MLIM. Richards is a member of the Board of Leaders of 2020 Women on Boards and is the recipient of the 100 Women in Hedge Funds 2014 European Industry Leadership Award.

Nouriel Roubini is the cofounder and chairman of Roubini Global Economics, an independent, global macroeconomic strategy research firm. The firm’s website, Roubini.com, has been named one of the best economics web resources by BusinessWeek, Forbes, The Wall Street Journal and The Economist . He is also a professor of economics at New York University’s Stern School of Business. From 1998 to 2000, he served as the senior economist for international affairs on the White House Council of Economic Advisors and then the senior advisor to the undersecretary for international affairs at the U.S. Treasury Department, helping to resolve the Asian and global financial crises, among other issues.

Bruce Zimmerman is CEO and Chief Investment Officer of The University of Texas Investment Management Company (UTIMCO). UTIMCO, investing over USD $30 billion, is the nation’s second largest manager of endowments. Prior to joining UTIMCO, Zimmerman was CIO and Global Head of Pension Investments at Citigroup, where he had previously been CFO and Chief Administrative Officer for Citigroup Alternative Investments.

The summit brings the world’s leading institutional investors, fund managers, academics, economists, regulators and professional services providers to the Cayman Islands – the world’s leading domicile for investment funds – to discuss and debate Supercharging the Alternative Investment industry.

For more information about the Cayman Alternative Investment Summit, please visit: http://www.caymansummit.com/ .

CONTACT:  Bonnie Finnigan: + 1(345) 640 3800 or bonnie.finnigan@dartcayman.com for more information

About the Cayman Alternative Investment Summit

The Cayman Alternative Investment Summit is an annual global conference designed to help shape, guide and sustain a vibrant alternative investment industry and provides a platform for the industry to share ideas, insights and networking opportunities. For more information, please visit  http://www.caymansummit.com/

For more information, contact: Kathryn Farmer 678-642-4301 kfarmer@thewilbertgroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 31

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Bank of Canada Considers Interest Rate Cuts Amid Growth Concerns

Updated Category News Views 91

Bank of Canada Considers Possible Rate Cuts Recent discussions reported by the Financial Times reveal that Governor Tiff Macklem of the Bank of Canada has started exploring the possibility of increasing the pace at which interest rates could be cut. This potential shift highlights the Bank's response to growing concerns about the Canadian economy's current dynamics....

Continue Reading
Photonics Market Poised for Massive Growth by 2030

Updated Category News Views 151

Understanding the Photonics Market Growth The photonics industry is on an impressive trajectory, with projections indicating it will grow significantly over the coming years. Experts foresee the market expanding from approximately USD 1,093.96 billion to an astounding USD 1,481.80 billion by 2030, reflecting a compound annual growth rate (CAGR) of around 6.3%. This rapid...

Continue Reading
Brookfield Infrastructure Plans Redemption of Preferred Units

Updated Category News Views 154

Brookfield Infrastructure Announces Series 3 Redemption Plan BROOKFIELD, News - Brookfield Infrastructure Partners L.P. (TSX: BIP.UN; NYSE: BIP) has announced its intention to redeem all outstanding Cumulative Class A Preferred Limited Partnership Units, Series 3 (the “Series 3 Preferred Units”). This strategic decision aims to enhance their portfolio's financial...

Continue Reading
How a $1000 Investment in Enphase Energy Grew to $3200

Updated Category News Views 147

Transforming $1000 into $3200 with Enphase Energy Investing can be a journey filled with uncertainties, but the story of Enphase Energy (NASDAQ: ENPH) reveals a powerful lesson in the potential of financial growth. Over the past five years, Enphase Energy has impressively outperformed many market benchmarks, achieving a remarkable annualized return of 26.49%. At present,...

Continue Reading
Investors Should Pay Attention: Rocket Pharmaceuticals Lawsuit Update

Updated Category News Views 191

The Class Action Lawsuit Against Rocket Pharmaceuticals Recently, investors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have been advised to participate in a class action lawsuit for potential securities fraud. This lawsuit arises from significant concerns over the company's disclosure practices and the impact of leadership decisions on stock performance. If you are an...

Continue Reading